Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

被引：19
|
作者：
Kolesar, Jill [1 ,2 ]
Huang, Wei [1 ,3 ]
Eickhoff, Jens [1 ,4 ]
Hahn, Kristine [1 ,5 ]
Alberti, Dona [1 ,5 ]
Attia, Steven [1 ,5 ]
Schelman, William [1 ,5 ]
Holen, Kyle [1 ,5 ]
Traynor, Anne [1 ,5 ]
Ivy, Percy [6 ]
Wilding, George [1 ,5 ]
机构：
[1] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Pharm, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat, Madison, WI 53792 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA
[6] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2009年 / 64卷 / 01期
关键词：
Triapine (R); 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; Ribonucleotide reductase; Automated quantitative immunohistochemistry (AQUA); Quantitative real time PCR; PHASE-II; CELL-PROLIFERATION; R2; COMPONENT; IN-VITRO; CANCER; OVEREXPRESSION; GEMCITABINE; TRANSFORMATION; RESISTANCE; INCREASES;
D O I：
10.1007/s00280-008-0845-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- A 0.94 SD, vs 0.41 +/- A 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- A 1.49 SD, vs 0.29 +/- A 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). RRM2 gene and protein expression varies by tumor type.
引用
收藏
页码：79 / 86
页数：8
相关论文
共 50 条
  • [21] The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers
    Huang, Yasheng
    Liu, Xiyong
    Wang, Yuan-Hung
    Yeh, Shauh-Der
    Chen, Chi-Long
    Nelson, Rebecca A.
    Chu, Peiguo
    Wilson, Timothy
    Yen, Yun
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 51.e9 - 51.e19
  • [22] Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone
    Liu, XY
    Zhou, BS
    Xue, LJ
    Qiu, WH
    Shih, J
    Zheng, S
    Yen, Y
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (08) : 1499 - 1511
  • [23] Serum Ribonucleotide Reductase Subunit M2 in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma
    Jin, Xuehang
    Yu, Wei
    Wang, Ange
    Qiu, Yunqing
    LABORATORY MEDICINE, 2023, 54 (06) : 626 - 632
  • [24] E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2
    Fang, Zejun
    Gong, Chaoju
    Liu, Hong
    Zhang, Xiaomin
    Mei, Lingming
    Song, Mintao
    Qiu, Lanlan
    Luo, Shuchai
    Zhu, Zhihua
    Zhang, Ronghui
    Gu, Hongqian
    Chen, Xiang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (02) : 407 - 415
  • [25] Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein
    Liu, Xia
    Xu, Zhijian
    Hou, Chuanwei
    Wang, Meng
    Chen, Xinhuan
    Lin, Qinghui
    Song, Rui
    Lou, Meng
    Zhu, Lijun
    Qiu, Yunqing
    Chen, Zhi
    Yang, Chunhao
    Zhu, Weiliang
    Shao, Jimin
    BIOCHEMICAL PHARMACOLOGY, 2016, 103 : 118 - 128
  • [26] Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma
    Zou, Yun
    Zhou, Juan
    Xu, Bin
    Li, Wenzhi
    Wang, Zhong
    ONCOTARGETS AND THERAPY, 2019, 12 : 3267 - 3275
  • [27] Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
    Morikawa, Teppei
    Maeda, Daichi
    Kume, Haruki
    Homma, Yukio
    Fukayama, Masashi
    HISTOPATHOLOGY, 2010, 57 (06) : 885 - 892
  • [28] Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy
    Fisher, Sarah B.
    Fisher, Kevin E.
    Patel, Sameer H.
    Lim, Matthew G.
    Kooby, David A.
    El-Rayes, Bassel F.
    Staley, Charles A., III
    Adsay, N. Volkan
    Farris, Alton B., III
    Maithel, Shishir K.
    CANCER, 2013, 119 (02) : 454 - 462
  • [29] Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma
    Das, Basudeb
    Jain, Neha
    Mallick, Bibekanand
    GENE, 2022, 808
  • [30] Serum level and tumor tissue expression of Ribonucleotide-diphosphate Reductase subunit M2 B: a potential biomarker for colorectal cancer
    Mobarra, Naser
    Gholamalizadeh, Hanieh
    Abdulhussein, Kaed A.
    Raji, Sara
    Asl, Fatemeh Taheri
    Mirvahabi, Mobina Sadat
    Rafiee, Mahdi
    Pakzad, Reza
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (05) : 3657 - 3663
12345